Introduction
The differentiation and development of skeletal muscle provides a good system to study gene products which are involved in the cascade of molecular and cellular events that lead to terminal differentiation.
The muscle basichelix-loop-helix (bHLH) proteins (MyoD, Myogenin, MyfS, MRF4) are potent inducers of the myogenic program and act as muscle-specific transcription regulators, i.e. they can activate the program for skeletal muscle differentiation when introduced into non-muscle cells (reviewed in Emerson, 1990; Olson, 1990; Lassar and Munsterberg, 1994) . During mouse embryogenesis, in situ hybridization studies have revealed that these myogenic regulators are present in myogenie cells at sites destined to give rise to cells of the skeletal muscle lineage, consistent with their role as muscle-specific determining factors (reviewed in Lyons and Buckingham, 1992; Sassoon, 1992) . Gene knockout technology has also demonstrated the importance and hierarchical relationship of bHLH proteins in muscle formation Rudnicki et al., 1992 Rudnicki et al., , 1993 Hasty et al., 1993) .tors may be involved in skeletal muscle determination. One such candidate factor is the myocyte-specific enhancer factor-2 (MEF2) protein. This protein has musclespecific DNA binding activity, recognizing conserved A/T rich element in the regulatory regions of numerous muscle-specific genes (Gosset et al., 1989) . MEF2 binding sites are essential for the high expression levels of a number of striated muscle-specific genes (Edmondson et al., 1992; Yu et al., 1992) . Interestingly, MEF2 binding sites are juxtaposed to one or more muscle bHLH factor DNA-binding sites in the regulatory regions of some of these muscle-specific genes (Wentworth et al., 1991; Amacher et al., 1993) . MEF2 binding sites are also present in a number of cardiac muscle genes and seem to be essential for cardiac muscle transcription (Zhu et al., 1991; Navankasattusas et al., 1992) . The Four MEF2 genes which have been cloned from humans and mice belong to the evolutionarily ancient MADS domain family of transcription factor proteins (Pollock and Treisman, 1991; Yu et al., 1992; Leifer et al., 1993; Martin et al., 1993 Martin et al., , 1994 McDermott et al., 1993) . Alternative splicing of the MEF2 primary transcripts result in additional isoforms, thereby providing further complexity to this family of regulators. All MEF2 isoforms are highly conserved in the MADS domain and an adjacent region but differ in their carboxy-termini.
In contrast to myogenic bHLH proteins, which are only expressed in striated skeletal muscles, the MEF2 proteins are expressed in all muscle types, deriving from skeletal, cardiac and smooth muscle lineages (Chambers et al, 1992; Yu et al., 1992; Breitbart et al., 1993; Martin et al., 1993) .
It has been shown that forced expression of myogenin or MyoD induces MEF2 activity along with myogenic differentiation in a variety of non-muscle cells (Cjersi et al., 1991; Lassar et al., 1991) . However, there is an essential MEF2 binding site in the regulatory region of the myogenin gene (Edmondson et al., 1992) and proper regulation of myogenin expression in transgenic mice requires both the bHLH and MEF2 binding sites within the myogenin promoter region (Cheng et al., 1993; Yee and Rigby, 1993) . Moreover, cooperativity between MEF2 and myogenic bHLH factors has been demonstrated to occur through direct physical interaction (Kaushal et al., 1994 , MoIkentin et al., 1995 .
Recent in situ hybridization studies using mouse MEF2 probes have shown that MEF2 gene transcripts are detected very early in development at high levels in the myogenic cells of the myotome and embryonic heart (Edmondson et al., 1994) . MEF2A and MEF2D transcripts have, however, been detected in many cell types where they are either not translated or the corresponding proteins are rapidly degraded . Therefore, it is important to establish temporal and spatial correlations between RNA and protein expression profiles.
In the present study, we have performed whole mount in situ immunohistochemistry of mouse embryos at different stages of development using polyclonal antibodies specific for the MEF2A, MEF2C and MEF2D isoforms. The results demonstrate that MEF2 proteins are expressed very early in development and localize to mesodermally derived regions which are associated with the formation of skeletal muscle and the heart. In addition, MEF2A is detected in non-muscle cells, possibly early cells of the vasculature which are also of mesodermal origin. Our finding that MEF2 proteins are in the heart and somites during early mouse embryogenesis indicates that MEF2 is important in both cardiac and skeletal muscle development, and that interactive pathways involving MEF2 and bHLH proteins are likely to exist for generating and maintaining the skeletal muscle program.
Results

Spatial and temporal expression of MEF2 proteins in the somites
MEF2 proteins are spatially and temporally regulated during mouse embryogenesis.
These proteins are localized mainly in the somites and the heart (Fig. 1) . At 8.5-9 days p.c. MEF2A initially appears in regions ventral to the somites and between the somites (Figs. IA and 4A) . Then, at day 9 p.c. (13-15 somites) a few MEF2A- to the heart (stars, arrowhead) and somites (arrows). All the three MEF2 isoforms are seen in the heart by 8.5 days of development (A-C). The MEFX protein staining is intense in the outflow regions of the heart (B, ring). By day 9.5-10 pc. all MEF2 isoforms show prominent staining of the heart (I-K), which persists through day 11.5 of development (Q-S). In the somites. the localization of the MEF2 isoforms proceeds in the rostra-caudal direction with the MEF2D isoform being detected later than the other two isoforms (I-K). The MHC follows the same pattern as MEF2A and MEF2C and closely correlates with their presence in the somites. Pre-immune antibodies were used as controls and did not show any staining (data not shown). (A-D) 8.5-9 day embryos, (E-H) 9-9.5 day embryos, (I-L) 9.5-10 day embryos, (M-P) 10.5-l 1 day embryos, (Q-T) 11.5 day embryos. T.
):I positive cells are detected in the dorso-central region of the first one or two somites in addition to the intersomitic region (Fig. ZA, arrows) . By day 9.5 of development, approximately the first six somites have MEF2A-positive cells in the dorso-central region of the somites (Figs. 1E and 2E) . At day 9.5 p.c., the intersomitic staining has also lost its prominence in the more rostra1 somites but remains intense in the caudal somitic region, where MEF2A-positive cells are not yet detectable in the center of somites. Under higher magnification, it is clear that the staining is detected mainly in the nucleus, which appears round to oval in shape (Fig. 21) . By this stage, the staining for MEF2A has also extended to approximately 16-l 8 somites ( Fig. 11 ) and more cells, scattered in the center of the somite, are stained ( Fig. 21) . At day 10.5-I 1, the number of positively stained somites increases to approximately 30 and they appear as condensed rows in the rostra1 somites ( Fig. IM) and are more well-spread in the caudal region (Fig. 3D) . By day 11, the MEF2A-positive cells in the caudal region have become condensed and all somites, including those in the caudal-most region, are stained. Additionally, at the junction of the forelimb bud, the MEF2A-positive cells extend into the ventral region of the somite (Figs. 1M and 2M, arrows), and this staining is more obvious by day 11.5 of development (Fig. lQ, arrow) .
The MEF2C protein first appears at day 9 (13-15 somites) in a few cells in the center of the first one or two rostral-most somites. As observed with MEF2A, MEF2C staining proceeds rostro-caudally with staining being detected in 4-5 of the rostra1 most somites at day 9-9.5 p.c. (Figs. 1F and 2F, arrows) . Approximately 25-27 somites show MEF2C-positive cells by day 10.5-l 1 of development (Fig. 1N ). Similar to the MEF2A isoform, the MEF2C-positive cells are seen as streaks in the middle of the condensed somite (Figs. 1N and 2N, arrows). As development proceeds, the number of MEF2C-positive cells increases within each somite. However, the pattern of MEF2C staining differs from the staining pattern of MEF2A in that there are no MEF2C-positive cells in the intersomitic region, and MEF2C expression is restricted to the somites and heart.
In contrast to MEF2A and MEF2C, MEF2D staining is first discernible, albeit faintly, at day 10-10.5 of development in the center of the somites. As development proceeds, the MEF2D staining pattern is similar to that of MEF2A and MEF2C, and also appears as dorso-ventral streaks in the midline of the somites (Figs. 10 and 20, arrows) . In general, the pattern of MEF2D staining in cells of the somites exhibits a similar pattern as that of MEF2C, although it is much weaker. This could reflect either a difference in affinity between the two antibodies or a lower abundance of the MEF2D protein.
At early developmental stages, when MEF2 proteins appear in the somites, myosin heavy chain (MHC) staining is not detected in the somites. However, MHC staining is observed shortly after MEF2 protein expression, and follows the same pattern as MEF2A and MEF2C in the somites after day 9 of development. By day 9.5, MHC is also seen in the four most rostra1 somites (Figs. 1H and 2H, arrows). The close correlation between the presence of MEF2 proteins and MHC staining is further supported by data from double labeling studies in which 9.5 day embryos show co-localization of MEF2A and MHC in the rostra1 2-3 somites, while the more caudal somites only stain for MEF2A but not MHC (data not shown).
In summary, the MEM protein staining pattern follows the pattern described for the morphological reorganization of somites during development (Sassoon et al., 1989) . At day 9.5 of development, MEF2 protein is initially expressed in the central and dorsal regions of the somites. Expression then extends ventrally as development proceeds and somites mature, and by day 11 of development, MEF2 appears as streaks in the center of the somites extending dorso-ventrally.
The intensity of protein staining decreases after day 12 of development as the musculature develops, although faintly positive cells can be seen in the tail, heart and ventral body wall in the region of intercostal muscles (data not shown). Overall, the MEF2A protein appears to be the predominant isoform being expressed at high levels, as indicated by the intense staining and by the presence of a greater number of MEF2A-positive cells. The intense staining could, however, be partly due to the higher affinity of this antibody as compared to the other MEF2 antibodies.
At1 MEF2 proteins are detected in early cardiac development
At day 8.5 p.c. all three MEF2 protein isoforms are detected in the heart (Fig. 1, see star) . The staining is punctate in appearance, probably reflecting nuclear localization. At this stage of development, the heart is Sshaped with a pronounced ventral curvature that delineates the region of the ventricular dilatation and the bulbar region is continuous cranially with the myocardial mantle (Kaufman, 1990) . MEF2A protein expression is initially detected at day 8.5 of development over the entire heart, including the outflow tract and ventricles (Figs. 1A and  4D) . By day 9.5-10 p.c. there is prominent staining of the heart which persists through day 11.5 of development (Fig. lA,E,I ,M,Q, star and/or arrowhead). MEF2C is also present in the heart at day 8.5 p.c. and it is initially concentrated over the region of the outflow tract (Fig. IB,  ring) . By day 9.5-10 p.c. the intensity of MEF2C staining increases and becomes detectable in the ventricles (Fig 1 J,  star) . This expression continues until day 11 p.c. (Fig. lN,  star) , after which it starts to decline. MEF2D expression is detected in the heart at day 8.5 p.c. and becomes intense from day 9.5 to day 11.5 of development ( 8.5 of development onwards (Fig. ID,H ,L,P,T, star and/or arrowhead).
MEF2A proteins are also present in cells of nonmuscle lineage
MEF2A staining is also observed throughout the embryo, in cells of non-muscle lineage. In 9.5 day embryos, staining is observed in dispersed cells over the head region and surrounding the optic pit, as well as on structures resembling blood vessels in the midbrain (see Fig.  3A ). Indeed, this pattern becomes more organized and by day 10.5 of development, MEF2A-positive cells are seen to line the brain vesicles (Fig. 3B) . As previously described, MEF2A-positive cells are present at sites between the somites and outlining the ventral boundary of the somites of 8.5 day embryos. At day 9.5 p.c. the tail region corresponding to the caudal somites has the same pattern of intersomitic staining (Fig. 3C ) as seen in less mature embryos. Notably, MEF2A-positive cells are present on either side of the neural tube (Fig. 3C) . However, by day 10.5 p.c. both the intersomitic staining pattern of the caudal somites and the staining in the region adjacent to the neural tube are diminished, although there are numerous MEF2A-positive cells in the somites which exhibit a pattern similar to the morphology of the somites (Fig. 3D) . In the limb buds of 10.5 day embryos, MEF2A is present in dispersed cells (Fig. 3E, arrows) scattered over the entire region of the bud. This pattern differs from the MEF2 staining seen in the fore and hindlimb of 11.5 day embryos, where MEFZA-positive cells are confined to a region in the proximal area of the limb (Fig. 3F , arrow) which also stains for MHC. This pattern suggests that MEF2A is present in cells of non-myogenic lineage at an early developmental stage and these could represent precursor cells of the vasculature, neural crest cells or mesenchymal cells.
Since MEF2A staining is seen in cells of the nonmuscle lineage which are at vascularized regions, 8.5 day old embryos were incubated with antibodies specific for MEF2 and VWF (Von Willebrand factor), an endothelial cell marker. Both MEF2A and VWF proteins are detected in 8.5 day old embryos (9-12 somites) in vascularized areas of the embryo including the aorta and intersomitic vessels (Fig. 4) . However, dispersed MEF2A-positive cells are also present in regions of the embryo which are negative for VWF (Fig. 4A-C straight arrows) .
In summary (see Table I ), MEF2 proteins are detected early in development in the somites and heart, in accordance with the mRNA data (Edmonson et al., 1994) , thus suggesting that they are important in the earlier stages of the hierarchical cascade of myogenesis. In addition, their presence in non-muscle cells suggests that MEF2 could also play a role in the determination of other mesodermal derivatives such as the cells of vasculature.
3. Discussion
The spatial and temporal appearance of MEF2 isoforms
Our results demonstrate that MEF2A, MEF2C and MEF2D proteins are present early in development and are mainly restricted to the regions of skeletal and cardiac muscle differentiation.
All three isoforms examined are first detected in the heart of 8.5 day embryos. This is consistent with the observation that RNA transcripts of all three isoforms are also present in the heart at this stage (Edmondson et al., 1994) .
MEF2 proteins are present in the somites of mouse embryos at early developmental stages. Somites, which are mesodermal structures that give rise to the vertebrate skeletal muscle, appear at about 8 days p.c. in the mouse embryo and resemble balls of epithelial-like cells (Sassoon et al., 1989) . These cells differentiate by 9-9.5 days p.c. into the dermamyotome and sclerotome which will contribute to skin/muscle and skeletal structures, respectively. By day 9.5 of mouse development, the myotome forms in the central region of the somite as a result of migration of cells from the dermamyotome.
As development proceeds, the somite is composed of mononucleated myocytes which give rise to myotomal muscles. Cells at the lateral edge of the dermamyotome migrate laterally to give rise to limb musculature (reviewed in Wachtler et al., 1992) . MEF2A and MEF2C proteins are first detected in a discrete population of cells in the rostral-most somites of 9 day old embryos. The number of MEF2-positive fd, foregut diverticulum; s, somite; h, heart; ov, optic vesicle.
cells increases in older embryos and their expression pattern shows a rostro-caudal progression which parallels the maturation of the somites. In addition, MEF2 protein expression is nuclear, as expected from its role as a DNAbinding transcription factor. Indeed, by day 9.5-10 of development, MEFZpositive nuclei are in the central region of somites, and are flattened and spindle-shaped, representing the nuclei of the myocytes which compose the myotomal muscle segments in the center of the somite. Since MEF2 transcripts are first detected in the rostra1 somites at day 9-9.5 of development (Edmondson et al., 1994) , there is no lag between transcription and translation of MEF2 gene products in myogenic cells of the somite.
It appears that the temporal appearance of MEF2 mRNA and protein in the somites and limb bud (see below) is not strictly correlated. Edmondson et al. (1994) reported that MEF2A transcripts appear after MEF2C in the somites and that MEF2 transcripts appeared in the limb bud at day 11.5 of development.
Our present data show that the MEF2A protein is present in the somites prior to the appearance of MEF2C, and that MEF2A-positive cells are in the limb bud at day 10.5 of development (see below). This difference could be due to different sensitivity in the methods of detection or reflect a difference in abundance and stability of MEF2 mRNA and/ or protein.
The expression of MEF2 versus expression of the myogenic regulatory factors
The description of the temporal and spatial appearance of transcripts that code for the myogenic regulatory factors (MRF) has been well studied in mammalian development (reviewed in Buckingham, 1992; Sassoon, 1993) . In rodents, Myf5 is the first myogenic factor to be detected. Myogenin transcripts are detected at day 8.5 P.C. MRF4 RNA is also detectable at this time, while MyoD is not present until a full day after the appearance of myogenin/MRF4.
The MRF proteins appear in the same sequence as the mRNA and each MRF protein is first detectable within a few hours of the first appearance of its mRNA (Smith et al., 1994) . Our present report also shows that the MEF2 proteins appear at approximately the same time as the transcripts (Edmondson et al., 1994) . However, significant detection of the MEF2D protein is seen only at IO-IO.5 days of development.
This may be as a result of the decreased sensitivity of detection with the MEF2D antibody.
The expression of MEF2A and 2C protein is seen in the dorso-central region of the rostra1 somite by day 9 of development, and as somites mature, its expression is detected in both the dorsal and ventral region of the somites. Interestingly, Smith et al. (1994) have recently reported that Myf5 protein-expressing cells are located in the most dorsal portion of the somite nearest the neural tube, whereas the myogenin-positive cells are found in both the dorsal and ventral halves. In addition, at day 9 of development, myogenin protein expression is seen in the first 6-7 somites whereas our results show that MEF2 expression is detected only in the first 2-3 somites, thus indicating that in somites myogenin protein expression may precede MEF2 protein expression by a brief period. At this stage MHC-positive cells are not detected in the somites, but as development proceeds MHC-positive cells appear in a rostro-caudal pattern, similar to the pattern of MEF2 expression.
Within the limb buds Myf-5 expression is first observed at 10.5 days of development, while myogenin and MyoD expression is detectable beginning half a day later (Ott et al., 1991) . Similarly, MEF2A-positive cells are also seen in the limb bud at 10.5 days of development. However, the diffuse pattern of staining is in contrast to that exhibited by Myf-5 cells, which exist as proximal/distal groups in the limb bud (Ott et al., 1991) . As will be discussed later, these MEF2A-positive cells may also represent non-myogenic cells.
MEF2A in cells of non-muscle lineage
The results from the present immunocytochemical study also show that MEF2A, in addition to being a marker for the muscle lineage, could also be an early marker for cells of the vasculature. In the embryo the emergence of endothelial cells and their linking up into a close vascular tree proceeds in parallel with somitogenesis (Pardanaud and Dieterlen-Lievre, 1993) . In early stage embryos, MEF2A is detected in dispersed cells over the embryo. In older embryos these cells become more organized and are seen in the aorta, intersomitic arteries, vessels of the head and capillary plexus in the dorsal region of the embryo. This pattern is similar to that reported for the expression of flk-1, a tyrosine kinase receptor, in endothelial cell precursors (Yamaguchi, et al., 1993) . The MEF2A-positive regions also stain for VWF which is a specific marker for endothelial cells. However, it is noteworthy that while the pattern of staining of the VWF factor is highly organized and localized to the regions of the vasculature, MEF2A is detected in vascular structures as well as in a dispersed manner in regions over the body and cephalic mesenchyme of the embryos which are not positive for VWF. These MEF2A+lVWF-cells may represent endothelial precursors, angioblasts or other migratory cells such as neural crest cells. Since MEF2 mRNA is expressed in embryonic vascular smooth muscle (Edmondson et al., 1994) some of these may also represent cells of the smooth muscle lineage. The observation that MEF2A may be an early marker for vasculogenesis leads to an interesting possibility where MEF2A may play an important role in the cues that direct spatial organization of blood vessels.
In the limb bud MEF2A-positive cells could represent cells of the vasculature or migratory myoblasts which are .anti-rabbit or anti mouse IgG from Boehringer Mannknown to colonize the limbs (Ordahl and Le Douarin, heim) at a dilution of 1:250. Notably, the embryos were 1992). It is noteworthy that the pattern of VWF staining washed in PBSMT five times for 1 h each at room temin the limb buds differs from that of MEF2 (data not perature before and after the incubation with the seconshown). Therefore, a portion of the dispersed cells seen in dary antibody. The detection of the peroxidase was done 10.5 day embryo limb buds may represent migratory cells using the DAB-peroxidase kit from Vector Laboratories. which colonize the limb. It is speculated that in this re-
The embryos were washed in PBT (0.2% BSA, 0.1% gion these cells may receive additional inductive signals Triton X-100 in PBS) before and after the color developand subsequently express myogenic bHLH regulators and ment reaction. They were then dehydrated through a muscle-specific proteins (Lassar and Munterberg, 1994) . methanol series and cleared in benzyl alcohol/benzyl benIndeed, at day 11.5 of development MEF2A-positive cells zoate (1:2). Throughout the entire protocol, the embryos are seen as a group of cells in the proximal region of the were gently rocked. Visualization and photography were limb and this area also contains positive MHC cells. done using a Zeiss Axiophot microscope. In conclusion, this study documents the presence of MEF2 proteins in cells of the cardiac and skeletal muscle lineages at an early stage in development.
In addition, their presence in cells of the vasculature suggests a role for these proteins in vasculogenesis.
MEF2 proteins could therefore constitute common denominators of commitment to certain cell lineages while additional specificity is conferred by interactions with cell-specific cofactors.
Experimental procedures
I. Collection of embryos
CD1 albino mice, which were pregnant for 8.5, 9.5, 10.5 and 11.5 days p.c., were obtained from the Charles River Facility. The day of vaginal plug formation was taken as day 0.5 of pregnancy. In some cases, C57 Bl/6 mice were set up for mating in the animal facility at Children's hospital. The mice were sacrificed by carbon dioxide inhalation and the embryos were carefully dissected out from the extra-embryonic membranes into phosphate buffered saline (PBS). In addition to the date of pregnancy, the morphology of the embryos including neural fold closure and the number of somites, was observed carefully under a dissection microscope for more accurate determination of the developmental stage.
The primary antibodies used for the immunocytochemistry are rabbit polyclonal antisera specific for MEF2A, 2C and 2D which were raised against pGEX-GST bacterial fusion proteins containing the C-terminal amino acids 272-507, 294-465 and 269-521, respectively, according to standard procedures. In brief, the respective fusion proteins were separated from the crude bacterial extracts by binding to glutathione Sepharose 4B and SDS-PAGE gel purified proteins were used to raise a polyclonal antiserum. Western blot analysis with cos cells transfected with the different isoforms did not reveal any crossreaction among the antibodies. The anti-MEF2 antibodies were used at a dilution of 1:lOOO in PBSMT, while the monoclonal anti-sarcomeric MHC (MF2D; Bader et al., 1982) and VWF antibodies (Diagnostica Stago) were used at a dilution of 1:lO and l:lOO, respectively. The same primary antibodies were reused for several experiments. The data presented includes observations from 8-10 experiments and pre-immune antibodies were used as controls in all experiments.
Acknowledgements
Whole mount in situ immunocytochemistry
Embryos were fixed in methanol/dimethyl sulfoxide (4:l) for 24 h at 4°C. and then bleached in a 1:1 solution of fixative and hydrogen peroxide for 4-6 h at room temperature. The embryos were subsequently stored in methanol at 4°C until further processing . The embryos were rehydrated successively in 80% methanol, 50% methanol, 15% methanol and PBS for 30 min each at room temperature. This was followed by two 1 h incubation periods in PBSMT (2% instant milk powder and 0.1% Triton X-100 in PBS) at room temperature and once in PBSMT plus 5% fetal calf serum for 0.5 h. The embryos were then incubated for 2-3 h at room temperature with the primary antibodies, followed by an incubation with the secondary antibody (peroxidase coupled goat
